An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection

Cardiovascular Research

Volumn 63, Issue 2, 2004, Pages 208-216

  Bogoyevitch, Marie A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HeartSearch   (Australia)

Author keywords

Apoptosis; In vitro cardioprotection; In vivo cardioprotection; Ischemia reperfusion damage; Phosphatidyl inositol 3 kinase

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

APOPTOSIS; BLOOD BRAIN BARRIER; CARDIOVASCULAR PERFORMANCE; CELL VIABILITY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; EXPERIMENTAL MODEL; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANIMALS; APOPTOSIS; ERYTHROPOIETIN; HUMANS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; NECROSIS; NEURONS;

EID: 3142598688     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.03.017     Document Type: Review

References (90)

1. Smith K.J., Bleyer A.J., Little W.C., Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59:2003;538-548
2. Krantz S.B. Erythropoietin. Blood. 77:1991;419-434
3. Dunn C.J., Markham A. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs. 51:1996;299-318
4. Ng T., Marx G., Littlewood T., Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad. Med. J. 79:2003;367-376
5. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol Med. 228:2003;1-14
6. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U. S. A. 100:2003;4802-4806
7. Cai Z., Manalo D.J., Wei G., et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 108:2003;79-85
8. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112:2003;999-1007
9. Tramontano A.F., Muniyappa R., Black A.D., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 2003;990-994
10. Moon C., Krawczyk M., Ahn D., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. U. S. A. 100:2003;11612-11617
11. Mitka M. Researchers probe anemia - heart failure link. JAMA. 290:2003;1835-1838
12. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88:2000;1474-1480
13. Masuda S., Okano M., Yamagishi K., et al. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 269:1994;19488-19493
14. Bernaudin M., Bellail A., Marti H.H., et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia. 30:2000;271-278
15. Masuda S., Nagao M., Takahata K., et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J. Biol. Chem. 268:1993;11208-11216
16. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 412:2001;641-647
17. Ruscher K., Freyer D., Karsch M., et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J. Neurosci. 22:2002;10291-10301
18. Prass K., Scharff A., Ruscher K., et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke. 34:2003;1981-1986
19. Sakanaka M., Wen T.C., Matsuda S., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4635-4640
20. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10526-10531
21. Siren A.L., Fratelli M., Brines M., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4044-4049
22. Celik M., Gokmen N., Erbayraktar S., et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. U. S. A. 99:2002;2258-2263
23. Bommer J., Alexiou C., Muller-Buhl U., Eifert J., Ritz E. Recombinant human erythropoietin therapy in haemodialysis patients - dose determination and clinical experience. Nephrol. Dial. Transplant. 2:1987;238-242
24. Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 321:1989;158-163
25. Shasha D., George M.J., Harrison L.B. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 98:2003;1072-1079
26. Buemi M., Allegra A., Corica F., et al. Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration. Nephrol. Dial. Transplant. 15:2000;422-423
27. Marti H.H., Gassmann M., Wenger R.H., et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int. 51:1997;416-418
28. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8:2002;495-505
29. Morishita E., Masuda S., Nagao M., Yasuda Y., Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 76:1997;105-116
30. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6741-6746
31. Wiessner C., Allegrini P.R., Ekatodramis D., et al. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J. Cereb. Blood Flow Metab. 21:2001;857-864
32. Fuste B., Serradell M., Escolar G., et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb. Haemost. 88:2002;678-685
33. Wolf R.F., Gilmore L.S., Friese P., et al. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb. Haemost. 77:1997;1020-1024
34. Squadrito F., Altavilla D., Squadrito G., et al. Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br. J. Pharmacol. 127:1999;482-488
35. Grasso G., Buemi M., Alafaci C., et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5627-5631
36. Chong Z.Z., Kang J.-Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 106:2002;2973-2979
37. Agnello D., Bigini P., Villa P., et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952:2002;128-134
38. Villa P., Bigini P., Mennini T., et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 198:2003;971-975
39. Shingo T., Sorokan S.T., Shimazaki T., Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci. 21:2001;9733-9743
40. Kawakami M., Sekiguchi M., Sato K., Kozaki S., Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 276:2001;39469-39475
41. Calapai G., Marciano M.C., Corica F., et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 401:2000;349-356
42. Damen J.E., Cutler R.L., Jiao H., Yi T., Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J. Biol. Chem. 270:1995;23402-23408
43. Verdier F., Chretien S., Billat C., et al. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate: 2. An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J. Biol. Chem. 272:1997;26173-26178
44. Vanhaesbroeck B., Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346:2000;561-576
45. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 114:2001;2903-2910
46. Alessi D.R., Caudwell F.B., Andjelkovic M., Hemmings B.A., Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 399:1996;333-338
47. Yaffe M.B., Leparc G.G., Lai J., et al. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat. Biotechnol. 19:2001;348-353
48. Blume-Jensen P., Janknecht R., Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8:1998;779-782
49. Kennedy S.G., Kandel E.S., Cross T.K., Hay N. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell. Biol. 19:1999;5800-5810
50. Ogawara Y., Kishishita S., Obata T., et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277:2002;21843-21850
51. Yamaguchi A., Tamatani M., Matsuzaki H., et al. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J. Biol. Chem. 276:2001;5256-5264
52. Oda E., Ohki R., Murasawa H., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058
53. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299
54. Chen C., Edelstein L.C., Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20:2000;2687-2695
55. Zong W.X., Edelstein L.C., Chen C., Bash J., Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 13:1999;382-387
56. Chu Z.L., McKinsey T.A., Liu L., et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10057-10062
57. Gottlieb R.A., Burleson K.O., Kloner R.A., Babior B.M., Engler R.L. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J. Clin. Invest. 94:1994;1621-1628
58. Theroux P., Willersen J.T., Armstrong P.W. Progress in the treatment of acute coronary syndromes. A 50-year perspective (1950-2000). Circulation. 102:2000;IV2-IV13
59. Eder H., Rosslenbroich B., Failing K. A dose-dependent effect of recombinant erythropoietin on the reticulocyte population of rats. Blut. 59:1989;184-187
60. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 102:2003;1340-1346
61. Bahlmann F.H., DeGroot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood. 103:2004;921-926
62. Ribatti D., Vacca A., Roccaro A.M., Crivellato E., Presta M. Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest. 33:2003;891-896
63. Ribatti D., Presta M., Vacca A., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 93:1999;2627-2636
64. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 64:2002;326-333
65. Rao S.V., Stamler J.S. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin. Auton. Res. 12:2002;141-143
66. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med. 340:1999;409-417
67. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339:1998;584-590
68. Wagner K.F., Katschinski D.M., Hasegawa J., et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood. 97:2001;536-542
69. Deten A., Shibata J., Scholz D., et al. Norepinephrine-induced acute heart failure in transgenic mice overexpressing erythropoietin. Cardiovasc. Res. 61:2004;105-114
70. Quaschning T., Ruschitzka F., Stallmach T., et al. Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J. 17:2003;259-261
71. Wang Q.D., Pernow J., Sjoquist P.O., Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc. Res. 55:2002;25-37
72. Heidbreder M., Frohlich F., Johren O., et al. Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J. 17:2003;1541-1543
73. Jung F., Palmer L.A., Zhou N., Johns R.A. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ. Res. 86:2000;319-325
74. Dame C., Sola M.C., Lim K.C., et al. Hepatic erythropoietin gene regulation by GATA-4. J. Biol. Chem. 279:2004;2955-2961
75. Dai Y.S., Cserjesi P., Markham B.E., Molkentin J.D. The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J. Biol. Chem. 277:2002;24390-24398
76. Matsui T., Li L., del Monte F., et al. Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocyts in vitro. Circulation. 100:1999;2373-2379
77. Matsui T., Tao J., del Monte F., et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 104:2001;330-335
78. Taniyama Y., Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J. Mol. Cell. Cardiol. 34:2002;1241-1247
79. Cook S.A., Sugden P.H., Clerk A. Regulation of Bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes. Association with changes in mitochondrial membrane potential. Circ. Res. 85:1999;940-949
80. Wu W., Lee W.L., Wu Y.Y., et al. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J. Biol. Chem. 275:2000;40113-40119
81. Cook S.A., Matsui T., Li L., Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J. Biol. Chem. 277:2002;22528-22533
82. Proud C.G., Denton R.M. Molecular mechanisms for the control of translation by insulin. Biochem. J. 328:1997;329-341
83. Gao F., Gao E., Yue T.L., et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 105:2002;1497-1502
84. Bogoyevitch M.A., Gillespie-Brown J., Ketterman A.J., et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal protein kinases are activated by ischemia/reperfusion. Circ. Res. 79:1996;162-173
85. Park H.S., Kim M.S., Huh S.H., et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J. Biol. Chem. 277:2002;2573-2578
86. Fujita E., Jinbo A., Matuzaki H., et al. Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochem. Biophys. Res. Commun. 264:1999;550-555
87. Wencker D., Chandra M., Nguyen K., et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111:2003;1497-1504
88. Sterin-Borda L., Barcelo A.C., Bozzini C.E. Erythropoietin improves cardiac contractility in post-hypoxic mice. Br. J. Haematol. 121:2003;180-186
89. Stuckmann I., Evans S., Lasar A.B. Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev. Biol. 255:2003;334-349
90. Wald M.R., Borda E.S., Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J. Cell. Physiol. 167:1996;461-468